Funding for this research was provided by:
Neurofibromatosis Therapeutic Acceleration Program (330441.01.01.2016488.10)
Received: 18 August 2017
Accepted: 30 January 2018
First Online: 7 February 2018
Ethics approval and consent to participate
: This study was approved by the University of Alabama at Birmingham’s Institutional Review Board. All study participants provided written, informed consent.
: All study participants provided written, informed consent.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.